Graham G. Walmsley 4/A
4/A · Olema Pharmaceuticals, Inc. · Filed Nov 26, 2024
Insider Transaction Report
Form 4/AAmended
Graham G. Walmsley
Director
Transactions
- Sale
Common Stock
2024-06-04$14.85/sh−700,000$10,395,000→ 700,761 total(indirect: See note) - Sale
Common Stock
2024-06-04$14.85/sh−475,000$7,053,750→ 708,114 total(indirect: See note)
Footnotes (2)
- [F1]The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F2]The shares are held by Logos Opportunities Fund II LP ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.